Related Experiment Video
Updated: Jun 25, 2025
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.1K
Carbon Ion Radiation Therapy for Nonmetastatic Castration-Resistant Prostate Cancer: A Retrospective Analysis
Yuhei Miyasaka1,2, Hidemasa Kawamura1,2, Hiro Sato1,2
1Department of Radiation Oncology, Gunma University Graduate School of Medicine, Showa-machi, Maebashi, Gunma, Japan.
Advances in Radiation Oncology
|May 23, 2024
Summary
Carbon ion radiation therapy (CIRT) shows promising results for nonmetastatic castration-resistant prostate cancer (nmCRPC). This study found CIRT to be safe and effective, with high survival and local control rates in nmCRPC patients.
Area of Science:
- Radiation Oncology
- Urologic Oncology
- Medical Physics
Background:
- Photon radiation therapy for nonmetastatic castration-resistant prostate cancer (nmCRPC) yields unsatisfactory outcomes.
- Carbon ion radiation therapy (CIRT) demonstrates superior tumor control, particularly in radioresistant malignancies.
Purpose of the Study:
- To retrospectively evaluate the clinical outcomes of carbon ion radiation therapy (CIRT) for nonmetastatic castration-resistant prostate cancer (nmCRPC).
Main Methods:
- Retrospective analysis of 23 nmCRPC patients treated with CIRT (57.6 Gy in 16 fractions or 51.6 Gy in 12 fractions).
- Castration resistance diagnosed via PSA kinetics or androgen deprivation therapy changes.
- Exploration of clinical factors impacting patient prognosis.
Main Results:
- Median follow-up was 63.6 months.
- 5-year survival rates: Overall (87.5%), local control (95.7%), biochemical relapse-free (70.3%), clinical relapse-free (75.7%).
- One case of grade 3 hematuria and bladder tamponade; no grade 4+ toxicity observed.
Conclusions:
- CIRT demonstrates acceptable safety and favorable efficacy for nmCRPC.
- Findings support further investigation of CIRT for nmCRPC treatment.
